Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 13/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519324 | 0.92 | BDKRB1 (0.67) | BDKRB1KDM4EALDH1A1NPSR1 | |
| SCHEMBL2516427 | 0.89 | BDKRB1 (0.54) | BDKRB1POLBSMN1; SMN2ALDH3A1PSEN1 | |
| SCHEMBL2517774 | 0.84 | BDKRB1 (0.55) | BDKRB1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2533962 | 0.84 | BDKRB1 (0.54) | BDKRB1SMN1; SMN2ALDH3A1PSEN1PSEN2 | |
| SCHEMBL2521885 | 0.81 | BDKRB1 (0.55) | BDKRB1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2518681 | 0.80 | BDKRB1 (1.00) | BDKRB1POLBSMN1; SMN2 | |
| SCHEMBL2518683 | 0.80 | BDKRB1 (1.00) | BDKRB1POLBSMN1; SMN2 | |
| SCHEMBL2520198 | 0.80 | BDKRB1 (0.60) | BDKRB1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2520204 | 0.79 | BDKRB1 (0.59) | BDKRB1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2518523 | 0.79 | BDKRB1 (0.55) | BDKRB1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034827-B2 | Phenanthridine derivatives as bradykinin antagonists | Richter Gegeon Nyrt. (HU) | 2011-10-11 | — | — | US | disclosed |
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB2, BDKRB1, HRH2 | BDKRB1 2/4885POLB 3922/4885KDM4E 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.